Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | GRK2 | P25098 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | FLT4 | P35916 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30352878 | 1.00 | CES2 (0.42) | CES2CES1DGAT1PPARDGPR35 | |
| SCHEMBL20639833 | 0.89 | CES2 (0.42) | CES2CES1DGAT1PPARDKDM4E | |
| SCHEMBL14405776 | 0.87 | CES2 (0.41) | CES2CES1DGAT1PPARDGPR35 | |
| SCHEMBL17119708 | 0.87 | DGAT1 (0.37) | DGAT1PPARDKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL14332118 | 0.84 | CYP3A4 (0.43) | CES2CES1ALDH1A1TDP1MAPK14 | |
| SCHEMBL18664023 | 0.84 | CES2 (0.42) | CES2CES1KDM4EALDH1A1POLB | |
| SCHEMBL17120565 | 0.84 | CES2 (0.42) | CES2CES1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL18661269 | 0.84 | CES2 (0.42) | CES2CES1KDM4EALDH1A1POLB | |
| SCHEMBL30270028 | 0.83 | KAT6A (0.43) | CES2CES1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL20640043 | 0.83 | KAT6A (0.43) | CES2CES1KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3397629-B1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2023-04-19 | — | — | EP | disclosed |
| CN-109970629-B | Process for preparing antifungal compounds | 迈科维亚医药公司 | 2023-04-11 | — | — | CN | disclosed |
| US-11247981-B2 | Metalloenzyme inhibitor compounds | Mycovia Pharmaceuticals, Inc. (US) | 2022-02-15 | — | — | US | disclosed |
| CN-108779094-B | Metalloenzyme inhibitor compounds | NQP 1598公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-108347949-B | Antifungal compound method | NQP 1598公司 | 2021-08-13 | — | — | CN | disclosed |
| CN-108289457-B | Process for preparing antifungal compounds | 迈科维亚医药公司 | 2021-08-06 | — | — | CN | disclosed |
| EP-3349586-B1 | ANTIFUNGAL COMPOUND PROCESS | MYCOVIA PHARMACEUTICALS INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3349586-B1 | ANTIFUNGAL COMPOUND PROCESS | MYCOVIA PHARMACEUTICALS INC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-10836740-B2 | Antifungal compound process | Mycovia Pharmaceuticals, Inc. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836740-B2 | Antifungal compound process | Mycovia Pharmaceuticals, Inc. (US) | 2020-11-17 | — | — | US | disclosed |
| WO-2012177603-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012177603-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| US-8236962-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236962-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236962-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20110306644-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306644-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306644-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| WO-2011133875-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133875-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836740-B2 | Antifungal compound process | ERG28, CYP51A1, DPM1 | CES2 2044/4885CES1 2805/4885DGAT1 2334/4885 |
| US-11247981-B2 | Metalloenzyme inhibitor compounds | MMEL1, GPX1, MPO | CES2 286/4885CES1 198/4885DGAT1 1278/4885 |
| US-20110306644-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CES2 286/4885CES1 198/4885DGAT1 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.